Shenzhen Salubris Pharmaceuticals Co Ltd SZSE:002294:
SAYS CO PLANS TO SEEK HONG KONG LISTING
Shenzhen Salubris Pharmaceuticals Plans To Seek Hong Kong Listing
Earlier from Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A
- Shenzhen Salubris Pharmaceuticals Co: Q3 2025 saw 15.85% revenue growth and 30.19% net profit increase, led by new products
- Shenzhen Salubris Pharmaceuticals Co: Net profit rose 6.10% on 4.32% revenue growth, led by new drugs and medical device expansion
- Shenzhen Salubris Pharmaceuticals Co: Patented and new product growth offset generic drug declines, keeping Q1 profit stable
- Shenzhen Salubris Pharmaceuticals Co: 2024 revenue rose 19.22% to ¥4.01B, net profit up 3.71%, with strong R&D and cash dividend